Get started
Pacira BioSciences, Inc.Pacira BioSciences, Inc.Pacira BioSciences, Inc.

Pacira BioSciences, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals Bonds

PCRX chart


Full chart

PCRX upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪886.53 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−1.97 USD
Net income (FY)
‪41.95 M‬ USD
Revenue (FY)
‪674.98 M‬ USD
Shares float
‪44.58 M‬
Beta (1Y)
0.90

Employees


Employees (FY)
712
Change (1Y)
−3 −0.42%
Revenue / Employee (1Y)
‪948.00 K‬ USD
Net income / Employee (1Y)
‪58.93 K‬ USD

About Pacira BioSciences, Inc.


Sector
Health Technology
CEO
Frank D. Lee
Headquarters
Tampa
Website
pacira.com
Founded
2006
FIGI
BBG0018FQNS6
Pacira Biosciences, Inc. is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

PCRX news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

PCRX highest yielding bonds


PCRX5221546
Pacira Biosciences, Inc. 0.75% 01-AUG-2025
Yield to maturity
6.77%
Maturity date
Aug 1, 2025

Explore more bonds 

Frequently Asked Questions


The current price of PCRX is 19.47 USD — it has increased by 1.16% in the past 24 hours. Watch Pacira BioSciences, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Pacira BioSciences, Inc. stocks are traded under the ticker PCRX.
PCRX stock has fallen by −1.34% compared to the previous week, the month change is a 10.28% rise, over the last year Pacira BioSciences, Inc. has showed a −41.30% decrease.
We've gathered analysts' opinions on Pacira BioSciences, Inc. future price: according to them, PCRX price has a max estimate of 39.00 USD and a min estimate of 8.00 USD. Watch PCRX chart and read a more detailed Pacira BioSciences, Inc. stock forecast: see what analysts think of Pacira BioSciences, Inc. and suggest that you do with its stocks.
PCRX reached its all-time high on Feb 25, 2015 with the price of 121.95 USD, and its all-time low was 6.16 USD and was reached on Feb 16, 2011. View more price dynamics on PCRX chart.
See other stocks reaching their highest and lowest prices.
PCRX stock is 2.92% volatile and has beta coefficient of 0.90. Track Pacira BioSciences, Inc. stock price on the chart and check out the list of the most volatile stocks — is Pacira BioSciences, Inc. there?
Today Pacira BioSciences, Inc. has the market capitalization of ‪886.52 M‬, it has decreased by −3.18% over the last week.
Yes, you can track Pacira BioSciences, Inc. financials in yearly and quarterly reports right on TradingView.
Pacira BioSciences, Inc. is going to release the next earnings report on Feb 27, 2025. Keep track of upcoming events with our Earnings Calendar.
PCRX earnings for the last quarter are 0.79 USD per share, whereas the estimation was 0.70 USD resulting in a 12.14% surprise. The estimated earnings for the next quarter are 0.79 USD per share. See more details about Pacira BioSciences, Inc. earnings.
Pacira BioSciences, Inc. revenue for the last quarter amounts to ‪168.57 M‬ USD, despite the estimated figure of ‪169.55 M‬ USD. In the next quarter, revenue is expected to reach ‪180.22 M‬ USD.
PCRX net income for the last quarter is ‪−143.47 M‬ USD, while the quarter before that showed ‪18.89 M‬ USD of net income which accounts for −859.64% change. Track more Pacira BioSciences, Inc. financial stats to get the full picture.
No, PCRX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 25, 2024, the company has 712.00 employees. See our rating of the largest employees — is Pacira BioSciences, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Pacira BioSciences, Inc. EBITDA is ‪178.03 M‬ USD, and current EBITDA margin is 24.13%. See more stats in Pacira BioSciences, Inc. financial statements.
Like other stocks, PCRX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Pacira BioSciences, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Pacira BioSciences, Inc. technincal analysis shows the buy rating today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Pacira BioSciences, Inc. stock shows the sell signal. See more of Pacira BioSciences, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.